MedTrace Logo

Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants

NCT07784335 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-25

No results posted yet for this study

Summary

In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.

Conditions

  • Healhty

Interventions

DRUG

Huperzine A Oral Solution

Investigational huperzine A oral solution, administered orally in 4 sequential escalating multiple-dose cohorts to healthy adult participants.

DRUG

Placebo

Matching placebo, identical in appearance, taste and packaging to huperzine A oral solution, administered orally for multiple doses.

Sponsors & Collaborators

  • Wanbangde Pharmaceutical Group Co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-25
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07784335 on ClinicalTrials.gov